title: A truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin.
abstract: Targeted cell therapies are possible through the generation of recombinant fusion proteins that combine a toxin, such as diphtheria toxin (DT), with an antibody or other molecule that confers specificity. Upon binding of the fusion protein to the cell of interest, the diphtheria toxin is internalized which results in protein synthesis inhibition and subsequent cell death. We have recently expressed and purified the recombinant soluble porcine CTLA-4 both with and without N-glycosylation in yeast Pichia pastoris for in vivo use in our preclinical swine model. The glycosylated and non-N-glycosylated versions of this recombinant protein each bind to a porcine CD80 expressing B-cell lymphoma line (LCL13271) with equal affinity (K(D)=13 nM). In this study we have linked each of the glycosylated and non-N-glycosylated soluble porcine CTLA-4 proteins to the truncated diphtheria toxin DT390 through genetic engineering yielding three versions of the porcine CTLA-4 fusion toxins: 1) monovalent glycosylated soluble porcine CTLA-4 fusion toxin; 2) monovalent non-N-glycosylated soluble porcine CTLA-4 fusion toxin and 3) bivalent non-N-glycosylated soluble porcine CTLA-4 fusion toxin. Protein synthesis inhibition analysis demonstrated that while all three fusion toxins are capable of inhibiting protein synthesis in vitro, the non-N-glycosylated porcine CTLA-4 isoforms function most efficiently. Binding analysis using flow cytometry of the porcine CTLA-4 fusion toxins to LCL13271 cells also demonstrated that the non-N-glycosylated porcine CTLA-4 isoforms bind to these cells with higher affinity compared to the glycosylated fusion toxin. The monovalent non-N-glycosylated porcine CTLA-4 fusion toxin was tested in vivo. NSG (NOD/SCID IL-2 receptor γ(-)/(-)) mice were injected with porcine CD80(+) LCL13271 tumor cells. All animals succumbed to tumors and those treated with the monovalent non-N-glycosylated porcine CTLA-4 fusion toxin survived longer based on a symptomatic scoring system compared to the untreated controls. This recombinant protein may therefore provide a novel approach for in vivo depletion of porcine antigen presenting cells (APCs) for studies investigating the induction of transplantation tolerance, autoimmune disease and cancer treatment.
authors.affiliation: Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA.
authors.forename: Jaclyn Stromp
authors.initials: JS
authors.lastname: Peraino
authors.forename: Marian
authors.initials: M
authors.lastname: Schenk
authors.forename: Huiping
authors.initials: H
authors.lastname: Zhang
authors.forename: Guoying
authors.initials: G
authors.lastname: Li
authors.forename: Christina E
authors.initials: CE
authors.lastname: Hermanrud
authors.forename: David M
authors.initials: DM
authors.lastname: Neville
authors.forename: David H
authors.initials: DH
authors.lastname: Sachs
authors.forename: Christene A
authors.initials: CA
authors.lastname: Huang
authors.forename: Raimon
authors.initials: R
authors.lastname: Duran-Struuck
authors.forename: Zhirui
authors.initials: Z
authors.lastname: Wang
mesh_terms: D000818:Animals; D018122:B7-1 Antigen / Q000276:immunology / Q000378:metabolism; D060908:CTLA-4 Antigen / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D002460:Cell Line; D004167:Diphtheria Toxin / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D005434:Flow Cytometry; D006031:Glycosylation; D007167:Immunotherapy / Q000379:methods*; D000922:Immunotoxins / Q000008:administration & dosage* / Q000235:genetics / Q000378:metabolism; D053631:Interleukin Receptor Common gamma Subunit / Q000172:deficiency / Q000235:genetics; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D051379:Mice; D016688:Mice, Inbred NOD; D018345:Mice, Knockout; D016513:Mice, SCID; D010843:Pichia / Q000235:genetics / Q000378:metabolism; D011485:Protein Binding; D014176:Protein Biosynthesis; D011499:Protein Processing, Post-Translational; D011993:Recombinant Fusion Proteins / Q000378:metabolism / Q000494:pharmacology; D013552:Swine
chemical_list: D018122:B7-1 Antigen; D060908:CTLA-4 Antigen; D004167:Diphtheria Toxin; C507942:Il2rg protein, mouse; D000922:Immunotoxins; D053631:Interleukin Receptor Common gamma Subunit; D011993:Recombinant Fusion Proteins